Revived Attention for Adult Craniopharyngioma

Abstract

Craniopharyngioma as a rare tumor originating from cells of rathke’s pouch and representing 2–5% of all intracranial tumors is a rare and generally benign neoplasm of the central nervous system with two incidence peaks one in childhood and one after 40 years of age. Data on adult patients is scarce compared to childhood onset tumors, however the burden of disease caused by the tumors and related treatment options is significant. Clinical symptoms range from headaches, visual disability, cranial nerve affection or hypothalamic symptoms (e. g. morbid obesity) to endocrine disorders. Most symptoms are related to tumor mass effect. The current standard of diagnostics is the determination of serum hormone levels and contrast enhanced magnetic resonance imaging often resulting in surgical treatment which holds a key role in all treatment concepts and should follow a hypothalamus sparing path. Radiation therapy may prove beneficial as adjuvant therapeutic option or in recurrent tumor, especially papillary tumors may be targeted using BRAF-600 inhibitors, targeted therapies for adamantinomatous craniopharyngioma have not yet reached a stage of clinical testing. Although prognosis regarding overall survival is favorable, life expectancy may be reduced due to the tumor itself as well as due to treatment effects. An important aspect especially in the adult population is the reduction in quality of life which is comparable to primary malignant brain tumors and metastases, calling for individual patient specific treatment approaches.

Key words

Hypopituitarism - Insufficiencies - Cancer - Craniopharyngioma - QoL

Publikationsverlauf

Eingereicht: 06. Mai 2020
Eingereicht: 28. Juni 2020

Angenommen: 08. Juli 2020

Artikel online veröffentlicht:
04. August 2020

• References

• 1 Pekmezci M, Louie J, Gupta N. et al. Clinicopathological characteristics of adamantinomatous and papillary craniopharyngiomas: University of California, San Francisco experience 1985-2005. Neurosurgery 2010; 67: 1341-1349 discussion 1349 DOI: 10.1227/NEU.0b013e3181f2b583.
• 2 Larkin S, Karavitaki N. Recent advances in molecular pathology of craniopharyngioma. F1000Res 2017; 6: 1202 DOI: 10.12688/f1000research.11549.1.
• 3 Müller HL. Craniopharyngioma. Handb Clin Neurol 2014; 124: 235-253 DOI: 10.1016/b978-0-444-59602-4.00016-2.
• 4 Halac I, Zimmerman D. Endocrine manifestations of craniopharyngioma. Childs Nerv Syst 2005; 21: 640-648 DOI: 10.1007/s00381-005-1246-x.
• 5 Zoicas F, Schöfl C. Craniopharyngioma in adults. Front Endocrinol (Lausanne) 2012; 3: 46 DOI: 10.3389/fendo.2012.00046.
• 6 Kendall-Taylor P, Jonsson PJ, Abs R. et al. The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol 2005; 152: 557-567 DOI: 10.1530/eje.1.01877.
• 7 Mende KC, Kellner T, Petersenn S. et al. Clinical situation, therapy, and follow-up of adult craniopharyngioma. J Clin Endocrinol Metab 2020; 105 DOI: 10.1210/clinem/dgz043.
• 8 Daubenbuchel AM, Hoffmann A, Gebhardt U. et al. Hydrocephalus and hypothalamic involvement in pediatric patients with craniopharyngioma or cysts of Rathke's pouch: impact on long-term prognosis. Eur J Endocrinol 2015; 172: 561-569 DOI: 10.1530/EJE-14-1029.
• 9 Dandurand C, Sepehry AA, Asadi Lari MH. et al. Adult craniopharyngioma: case series, systematic review, and meta-analysis. Neurosurgery 2018; 83: 631-641 DOI: 10.1093/neuros/nyx570.
• 10 Muller HL, Merchant TE, Warmuth-Metz M. et al. Craniopharyngioma. Nat Rev Dis Primers 2019; 5: 75 DOI: 10.1038/s41572-019-0125-9.
• 11 Rucka E, Wedrychowicz A, Zygmunt-Gorska A. et al. Clinical symptoms at the diagnosis of the craniopharyngioma. Pediatr Endocrinol Diabetes Metab 2012; 18: 58-62
• 12 Daubenbuchel AM, Muller HL. Neuroendocrine Disorders in Pediatric Craniopharyngioma Patients. Journal of Clinical Medicine 2015; 4: 389-413 DOI: 10.3390/jcm4030389.
• 13 Gil-Simoes R, Pascual JM, Casas AP. et al. Intrachiasmatic craniopharyngioma: Assessment of visual outcome with optical coherence tomography after complete surgical removal. Surg Neurol Int 2019; 10: 7 DOI: 10.4103/sni.sni_292_18.
• 14 Müller HL. Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity. Curr Opin Endocrinol Diabetes Obes 2016; 23: 81-89 DOI: 10.1097/med.0000000000000214.
• 15 Puget S, Garnett M, Wray A. et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 2007; 106: 3-12 DOI: 10.3171/ped.2007.106.1.3.
• 16 Muller HL, Gebhardt U, Etavard-Gorris N. et al. Current strategies in diagnostics and endocrine treatment of patients with childhood craniopharyngioma during follow-up–recommendations in KRANIOPHARYNGEOM 2000. Onkologie 2005; 28: 150-156 DOI: 10.1159/000083671.
• 17 Muller HL. Diagnosis, treatment, clinical course, and prognosis of childhood-onset craniopharyngioma patients. Minerva Endocrinol 2017; 42: 356-375 DOI: 10.23736/S0391-1977.17.02615-3.
• 18 Snyder R, Fayed I, Dowlati E. et al. Pituitary Adenoma and Craniopharyngioma Collision Tumor: Diagnostic, Treatment Considerations, and Review of the Literature. World Neurosurg 2019; 121: 211-216 DOI: 10.1016/j.wneu.2018.10.048.
• 19 Allen J, Chacko J, Donahue B. et al. Diagnostic sensitivity of serum and lumbar CSF bHCG in newly diagnosed CNS germinoma. Pediatr Blood Cancer 2012; 59: 1180-1182 DOI: 10.1002/pbc.24097.
• 20 Heming M, Lohmann L, Schulte-Mecklenbeck A. et al. Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis. J Neuroimmunol 2020; 341: 577171 DOI: 10.1016/j.jneuroim.2020.577171.
• 21 Petereit HF, Reske D, Tumani H. et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 2010; 257: 1855-1863 DOI: 10.1007/s00415-010-5623-3.
• 22 Tahmoush AJ, Amir MS, Connor WW. et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 191-197
• 23 Ricklefs FL, Maire CL, Reimer R. et al. Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. J Extracell Vesicles 2019; 8: 1588555-1588555 DOI: 10.1080/20013078.2019.1588555.
• 24 Le Rhun E, Seoane J, Salzet M. et al. Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Cancer Lett 2020; 480: 24-28 DOI: 10.1016/j.canlet.2020.03.021.
• 25 Muller HL, Merchant TE, Puget S. et al. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol 2017; 13: 299-312 DOI: 10.1038/nrendo.2016.217.
• 26 Warmuth-Metz M, Gnekow AK, Müller H. et al. Differential diagnosis of suprasellar tumors in children. Klin Padiatr 2004; 216: 323-330 DOI: 10.1055/s-2004-832358.
• 27 Tsuda M, Takahashi S, Higano S. et al. CT and MR imaging of craniopharyngioma. Eur Radiol 1997; 7: 464-469 DOI: 10.1007/s003300050184.
• 28 Choi SH, Kwon BJ, Na DG. et al. Pituitary adenoma, craniopharyngioma, and Rathke cleft cyst involving both intrasellar and suprasellar regions: differentiation using MRI. Clin Radiol 2007; 62: 453-462 DOI: 10.1016/j.crad.2006.12.001.
• 29 Muller HL. Craniopharyngioma. Endocr Rev 2014; 35: 513-543 DOI: 10.1210/er.2013-1115.
• 30 Karavitaki N, Brufani C, Warner JT. et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005; 62: 397-409 DOI: 10.1111/j.1365-2265.2005.02231.x.
• 31 Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI. et al. Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clin Neurol Neurosurg 2006; 108: 661-669 DOI: 10.1016/j.clineuro.2006.01.007.
• 32 Apps JR, Martinez-Barbera JP. Molecular pathology of adamantinomatous craniopharyngioma: Review and opportunities for practice. Neurosurg Focus 2016; 41: E4 DOI: 10.3171/2016.8.FOCUS16307.
• 33 Larkin SJ, Ansorge O. Pathology and pathogenesis of craniopharyngiomas. Pituitary 2013; 16: 9-17 DOI: 10.1007/s11102-012-0418-4.
• 34 Larkin SJ, Preda V, Karavitaki N. et al. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol 2014; 127: 927-929 DOI: 10.1007/s00401-014-1270-6.
• 35 Schweizer L, Capper D, Holsken A. et al. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke’s cleft cysts. Neuropathol Appl Neurobiol 2015; 41: 733-742 DOI: 10.1111/nan.12201.
• 36 Buchfelder M, Schlaffer SM, Lin F. et al. Surgery for craniopharyngioma. Pituitary 2013; 16: 18-25 DOI: 10.1007/s11102-012-0414-8.
• 37 Flitsch J, Muller HL, Burkhardt T. Surgical strategies in childhood craniopharyngioma. Front Endocrinol (Lausanne) 2011; 2: 96 DOI: 10.3389/fendo.2011.00096.
• 38 Koutourousiou M, Fernandez-Miranda JC, Wang EW. et al. The limits of transsellar/transtuberculum surgery for craniopharyngioma. J Neurosurg Sci 2018; 62: 301-309 DOI: 10.23736/S0390-5616.18.04376-X.
• 39 Dalan R, Liew H, Goh LL. et al. The haptoglobin 2-2 genotype is associated with inflammation and carotid artery intima-media thickness. Diab Vasc Dis Res 2016; 13: 373-376 DOI: 10.1177/1479164116645247.
• 40 Liew KY, Narayanan P, Waran V. Endoscopic transsphenoidal resection of craniopharyngioma. J Neurol Surg B Skull Base 2018; 79: S203-S204 DOI: 10.1055/s-0037-1620243.
• 41 Forbes JA, Ordonez-Rubiano EG, Tomasiewicz HC. et al. Endonasal endoscopic transsphenoidal resection of intrinsic third ventricular craniopharyngioma: surgical results. J Neurosurg 2018; 1-11 DOI: 10.3171/2018.5.JNS18198.
• 42 Sankhla SK, Jayashankar N, Khan GM. Extended endoscopic endonasal transsphenoidal approach for retrochiasmatic craniopharyngioma: Surgical technique and results. J Pediatr Neurosci 2015; 10: 308-316 DOI: 10.4103/1817-1745.174457.
• 43 Elowe-Gruau E, Beltrand J, Brauner R. et al. Childhood craniopharyngioma: Hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 2013; 98: 2376-2382 DOI: 10.1210/jc.2012-3928.
• 44 Bogusz A, Boekhoff S, Warmuth-Metz M. et al. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr Connect 2019; 8: 481-492 DOI: 10.1530/EC-19-0074.
• 45 Takahashi H, Nakazawa S, Shimura T. Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children. J Neurosurg 1985; 62: 120-127 DOI: 10.3171/jns.1985.62.1.0120.
• 46 Hader WJ, Steinbok P, Hukin J. et al. Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children. Pediatr Neurosurg 2000; 33: 211-218 DOI: 10.1159/000055955.
• 47 Kilday JP, Caldarelli M, Massimi L. et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol 2017; 19: 1398-1407 DOI: 10.1093/neuonc/nox056.
• 48 Barriger RB, Chang A, Lo SS. et al. Phosphorus-32 therapy for cystic craniopharyngiomas. Radiother Oncol 2011; 98: 207-212 DOI: 10.1016/j.radonc.2010.12.001.
• 49 Kortmann RD. Different approaches in radiation therapy of craniopharyngioma. Front Endocrinol (Lausanne) 2011; 2: 100 DOI: 10.3389/fendo.2011.00100.
• 50 Muller HL, Gebhardt U, Schroder S. et al. Analyses of treatment variables for patients with childhood craniopharyngioma–results of the multicenter prospective trial Kraniopharyngeom 2000 after three years of follow-up. Horm Res Paediatr 2010; 73: 175-180 DOI: 10.1159/000284358.
• 51 Hu M, Jiang L, Cui X. et al. Proton beam therapy for cancer in the era of precision medicine. J Hematol Oncol 2018; 11: 136 DOI: 10.1186/s13045-018-0683-4.
• 52 Zaman A, Wu W, Bivona TG. Targeting Oncogenic BRAF: Past, Present, and Future. Cancers (Basel). 2019 11. DOI: 10.3390/cancers11081197
• 53 Kared H, Tan SW, Lau MC. et al. Immunological history governs human stem cell memory CD4 heterogeneity via the Wnt signaling pathway. Nat Commun 2020; 11: 821 DOI: 10.1038/s41467-020-14442-6.
• 54 Brastianos PK, Shankar GM, Gill CM. et al. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst 2016; 108 DOI: 10.1093/jnci/djv310.
• 55 Himes BT, Ruff MW, Van Gompel JJ. et al. Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg 2018; 1-5 DOI: 10.3171/2017.11.JNS172373.
• 56 Rao M, Bhattacharjee M, Shepard S. et al. Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. Oncotarget 2019; 10: 6038-6042 DOI: 10.18632/oncotarget.27203.
• 57 Apps JR, Carreno G, Gonzalez-Meljem JM. et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol 2018; 135: 757-777 DOI: 10.1007/s00401-018-1830-2.
• 58 Ozyurt J, Muller HL, Thiel CM. A systematic review of cognitive performance in patients with childhood craniopharyngioma. J Neurooncol 2015; 125: 9-21 DOI: 10.1007/s11060-015-1885-z.
• 59 Ozyurt J, Thiel CM, Lorenzen A. et al. Neuropsychological outcome in patients with childhood craniopharyngioma and hypothalamic involvement. J Pediatr 2014; 164: e874 DOI: 10.1016/j.jpeds.2013.12.010.
• 60 Toumba M, Stanhope R. Quality of life and psychological outcome in patients treated for craniopharyngioma. J Pediatr Endocrinol Metab 2006; 19: 11-13 DOI: 10.1515/jpem.2006.19.1.11.
• 61 Cannavo S, Marini F, Trimarchi F. Patients with craniopharyngiomas: therapeutical difficulties with growth hormone. J Endocrinol Invest 2008; 31: 56-60
• 62 Jacobsen MF, Thomsen ASS, Bach-Holm D. et al. Predictors of visual outcome in patients operated for craniopharyngioma - a Danish national study. Acta Ophthalmol 2018; 96: 39-45 DOI: 10.1111/aos.13483.
• 63 Sadashivam S, Menon G, Abraham M. et al. Adult craniopharyngioma: The role of extent of resection in tumor recurrence and long-term functional outcome. Clin Neurol Neurosurg 2020; 192: 105711 DOI: 10.1016/j.clineuro.2020.105711.
• 64 O'Steen L, Indelicato DJ. Advances in the management of craniopharyngioma. F1000Res 2018; 7 DOI: 10.12688/f1000research.15834.1.
• 65 Muller HL. Diagnostics, treatment, and follow-up in craniopharyngioma. Front Endocrinol (Lausanne) 2011; 2: 70 DOI: 10.3389/fendo.2011.00070.
• 66 Zhang C, Verma V, Lyden ER. et al. The Role of Definitive Radiotherapy in Craniopharyngioma: A SEER Analysis. Am J Clin Oncol 2018; 41: 807-812 DOI: 10.1097/COC.0000000000000378.
• 67 Olsson DS, Andersson E, Bryngelsson IL. et al. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab 2015; 100: 467-474 DOI: 10.1210/jc.2014-3525.
• 68 Reddy GD, Hansen D, Patel A. et al. Treatment options for pediatric craniopharyngioma. Surg Neurol Int 2016; 7: S174-S178 DOI: 10.4103/2152-7806.178570.
• 69 Muller H. Craniopharyngioma – a chronic disease. Swiss Med Wkly 2018; 148: w14548 DOI: 10.4414/smw.2018.14548.